Goldman Sachs
CRDF icon

Goldman Sachs’s Cardiff Oncology CRDF Stock Holding History

Goldman Sachs’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,472
Closed -$1.35M – 7105
2015
Q4 		$1.35M Hold
3,472
– – ﹤0.01% 4012
2015
Q3 		$1.42M Buy
+3,472
New +$1.82M ﹤0.01% 4129

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Goldman Sachs's CRDF Position: Q2 2026 in Review

Goldman Sachs reduced its Cardiff Oncology (CRDF) stake by 11% in Q2 2026, selling an estimated $23.5K and leaving 120,827 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #6259.

Goldman Sachs first reported a position in CRDF in Q2 2015 and has held it in 29 quarters since. The position peaked at $3.14M in Q2 2015. 104 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Goldman Sachs held 120,827 shares of Cardiff Oncology worth $157K as of Q2 2026.
  • Goldman Sachs sold 14,771 Cardiff Oncology shares in Q2 2026, an estimated $23.5K.
  • Cardiff Oncology made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6259 holding.
  • Goldman Sachs first reported a position in Cardiff Oncology in Q2 2015 and has held it in 29 quarters since.
  • Goldman Sachs's Cardiff Oncology position peaked at $3.14M in Q2 2015.
  • 104 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.